11) BIOPROTO
Abstract
Funds biomedical research focused on the nonclinical and early clinical development of therapeutic countermeasures against known and emerging viral, bacterial, and toxin biological warfare (BW) threats for which Food and Drug Administration (FDA)-approved therapeutics are limited or lacking. Program is ending FY24 to align to higher priority activities
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2025
- Source ID
- 63fd03ac889f634d70549017234fbe34